FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus

17 Oct 2026 0 comments

The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.

Source: NeurologyLive · Published 15 Oct 2026 · Imported 17 Oct 2026

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment